Institute of Personalized Medicine - PUMA IPM

Pharmacogenomics aims at understanding how variations in the human genome affect the response to medications.

Our researchers are working to generate new knowledge, and to develop tools and algorithms that can help in personalizing medicine utilizing a patient’s genetic profile and other factors to achieve maximum therapeutic benefit with minimum toxicity.

News

Pamala Jacobson received the Sara Evans Faculty Woman Scholar/ Leader Award from the University of Minnesota Women’s Center, Office for Equity and Diversity and was honored at their Celebrating Changemakers Awards event on October 11, 2018.

This session highlighted the social and cultural challenges associated with providing care to local Native American tribes in Minnesota, who face larger health disparities than other populations.

David S

David Stenehjem works in the rapidly growing field of outcomes research, which guides his research on midostaurin in FLT3-mutated acute myeloid leukemia.

Sam CallistoSamuel is a PhD Candidate in the Experimental and Clinical Pharmacology department. During his time in the program Samuel has pursued various avenues of research related to precision medicine in neuropharmacology with a focus on anti-seizure drugs.

Weekly Genomics Scan

This weekly update features emerging roles of human genomics, testing and interventions in a wide variety of noncommunicable diseases across the life span.

Precision Medicine Seminar Series

"A Functional Genomic Platform for Discovery of Novel Targeting Strategies in Acute Myeloid Leukemia"  

Presented by Jeffrey Tyner, PhD
Associate Professor of Cell, Developmental and Cancer Biology; Co-Director, Translational Oncology Program, Knight Cancer Institute, Oregon Health and Sciences University

 
Friday, May 3
2 PM - 3 PM
5-125 Moos Tower (TC); 302 Heller Hall (Duluth via ITV)
 
Dr. Jeffrey Tyner's research is focused towards: 1) identification of cancer-causing gene targets in cancer patients and 2) identification of patient-tailored, gene-targeted therapies. To accomplish these objectives, he has spent the past decade developing and implementing a functional screening approach whereby primary cells from hematologic malignancy patients can be tested ex vivo for sensitivity to a library of small-molecule inhibitors. This assay has now been cumulatively applied to over 2,000 patient specimens, and this large data set has been leveraged to inform findings that offer new diagnostic and therapeutic options.
 
This event is free and open to the public. Light refreshments will be served.

Pharmacogenomics
Conference

Genomic Testing to Individualize Drug Therapy

The 2018 Pharmacogenomics Conference on June 22 was at capacity with over 310 registrants in attendance.  Topics included: cancer somatic mutations and selection of targeted therapies, emerging PGx areas.  Read about the event here

University Precision Medicine Initiatives

Bringing together scientists, healthcare providers, patients and payers in the area of precision medicine to promote research, education and the use of precision medicine and health to improve human health.

Transforming health and advancing equity by generating precision treatments of disease to advance health outcomes for all Minnesotans.